Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial

FIGHT-101, a first-in-human study of potent and selective FGFR 1–3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

(2022) V. Subbiah et al.   ANNALS OF ONCOLOGY

Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations.

(2022) Aleksandra Franovic et al.   JOURNAL OF CLINICAL ONCOLOGY

FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?

(2022) Csongor G. Lengyel et al.   Life-Basel

Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review

(2022) Jia Zheng et al.   Frontiers in Chemistry

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

(2022) Guo‐Ming Shi et al.   Cancer Medicine

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

(2021) Milind M. Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study

(2021) Funda Meric-Bernstam et al.   Cancer Discovery

Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance

(2021) Fariba Dehghanian et al.   Scientific Reports

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1)

(2021) Jason Gotlib et al.   BLOOD

A Phase 2 Study of Futibatinib (TAS-120) in Patients with Myeloid or Lymphoid Neoplasms Harboring Fibroblast Growth Factor Receptor (FGFR) 1 Rearrangements

(2021) Jean-Jacques Kiladjian et al.   BLOOD

Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.

(2020) James M. Cleary et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

(2020) Young K. Chae et al.   JOURNAL OF CLINICAL ONCOLOGY

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

(2020) Phillip C. C. Liu et al.   PLoS One

Phase 1, First-in-Human Study of Futibatinib, a Highly Selective, Irreversible FGFR1–4 Inhibitor in Patients with Advanced Solid Tumors

(2020) R. Bahleda et al.   ANNALS OF ONCOLOGY

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer

(2020) Rohan Garje et al.   ONCOLOGIST

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

(2020) Melanie A. Krook et al.   BRITISH JOURNAL OF CANCER

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

(2019) Rastilav Bahleda et al.   CLINICAL CANCER RESEARCH

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

P1-156Preliminary results from fight-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies

(2019) Yasutoshi Kuboki et al.   ANNALS OF ONCOLOGY

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

(2018) Milind Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosis

(2018) Julia Elisabeth Fromme et al.   Oncotarget

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

(2018) Vincenzo Mazzaferro et al.   BRITISH JOURNAL OF CANCER

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

(2017) Hideo Saka et al.   INVESTIGATIONAL NEW DRUGS

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

(2017) Lucia Nogova et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

(2017) Jayaprakash D. Karkera et al.   MOLECULAR CANCER THERAPEUTICS